FDA OKs Extended-Release Exenatide for Children With T2D FDA OKs Extended-Release Exenatide for Children With T2D
This injectable medication is the second GLP-1 receptor agonist approved for pediatric type 2 diabetes, and the first with once-weekly administration.FDA Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - July 23, 2021 Category: Consumer Health News Tags: Diabetes & Endocrinology News Alert Source Type: news

Bydureon BCise (exenatide extended-release) Approved in the US for the Treatment of Type 2 Diabetes in Pediatric Patients Ages 10 Years and Older
WILMINGTON, Del.--(BUSINESS WIRE) July 23, 2021--AstraZeneca’s Bydureon BCise (exenatide extended-release), once-weekly injectable suspension has been approved in the US for the treatment of type 2 diabetes (T2D); to improve glycemic control... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - July 23, 2021 Category: Drugs & Pharmacology Source Type: news

Bydureon Bcise (exenatide)
Title: Bydureon Bcise (exenatide)Category: MedicationsCreated: 12/11/2020 12:00:00 AMLast Editorial Review: 12/11/2020 12:00:00 AM (Source: MedicineNet Diabetes General)
Source: MedicineNet Diabetes General - December 11, 2020 Category: Endocrinology Source Type: news

Drug Combo Offers Long-Term Glycemic Control in T2DM
FRIDAY, Nov. 6, 2020 -- For patients with type 2 diabetes and inadequate glycemic control, exenatide once weekly (QW) plus dapagliflozin shows clinically relevant efficacy and is well tolerated over 104 weeks, according to a study published in the... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - November 6, 2020 Category: Pharmaceuticals Source Type: news

Exenatide in T2DM in Spain: better outcomes, lower cost
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - July 31, 2019 Category: Drugs & Pharmacology Source Type: news

exenatide (Byetta)
Title: exenatide (Byetta)Category: MedicationsCreated: 7/8/2005 12:00:00 AMLast Editorial Review: 3/13/2019 12:00:00 AM (Source: MedicineNet Diabetes General)
Source: MedicineNet Diabetes General - March 13, 2019 Category: Endocrinology Source Type: news

Exenatide treatment alleviated symptoms of depression in patients
(IOS Press) Non-motor symptoms of Parkinson's disease (PD), such as depression, apathy, cognitive impairment, sleep disorders, and sensory symptoms, can have a greater impact on health-related quality of life than motor deficits. In a post hoc analysis of the exenatide-PD trial results, investigators found that patients on exenatide treatment experienced improvements in severity of depression, independent of whether their motor function improved. They report their findings in the Journal of Parkinson's Disease. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - August 1, 2018 Category: International Medicine & Public Health Source Type: news

Incretin/SGLT-2 Combo Efficacy Persists 2 Years
(MedPage Today) -- Exenatide plus dapagliflozin maintained biomarker benefits in long-term study (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - June 26, 2018 Category: Cardiology Source Type: news

AstraZeneca ’ s once-weekly diabetes drug wins expanded FDA approval
AstraZeneca (NYSE:AZN) said today that the FDA approved its extended-release formulation of exenatide, Bydureon, for use as an add-on therapy to basal insulin in adults with Type II diabetes. The company’s once-weekly GLP-1 injectable was first approved in the U.S. in 2012. Get the full story at our sister site, Drug Delivery Business News. The post AstraZeneca’s once-weekly diabetes drug wins expanded FDA approval appeared first on MassDevice. (Source: Mass Device)
Source: Mass Device - April 3, 2018 Category: Medical Devices Authors: Sarah Faulkner Tags: Diabetes Drug-Device Combinations Food & Drug Administration (FDA) Pharmaceuticals Regulatory/Compliance Wall Street Beat AstraZeneca plc Source Type: news

FDA Approves Bydureon (exenatide extended-release) for Use with Basal Insulin in Patients with Type 2 Diabetes with Inadequate Glycemic Control
April 3, 2018 AstraZeneca today announced the US Food and Drug Administration (FDA) has approved Bydureon (exenatide extended-release) for injectable suspension as an add-on therapy to basal insulin in adults with type 2 diabetes (T2D) with... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - April 3, 2018 Category: Drugs & Pharmacology Source Type: news

Exenatide (BYDUREON) Extended Release for Injectable Suspension (New - Discontinuation)
Drug Shortage (Source: FDA Drug Shortages)
Source: FDA Drug Shortages - March 28, 2018 Category: Drugs & Pharmacology Source Type: news

Exenatide Influence on the Cardiac Sympatho-Vagal Balance Exenatide Influence on the Cardiac Sympatho-Vagal Balance
A new study examines the sympatho-vagal balance variations among patients with type 2 diabetes during treatment with the GLP-1 agonist exenatide.Journal of the Endocrine Society (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - March 5, 2018 Category: Consumer Health News Tags: Diabetes & Endocrinology Journal Article Source Type: news

Intarcia slashes headcount after FDA rejects diabetes drug-device combo
Four months after the FDA rejected its diabetes drug-eluting implant, privately-held Intarcia Therapeutics has cut 60 employees and received a clinical hold for two of its ongoing marketing studies, according to reports. The company’s device is designed for the continuous, subcutaneous delivery of exenatide in people with Type II diabetes. It was rejected by the U.S. regulatory agency in September, after the FDA found problems with the manufacturing process used to make ITCA 650. Get the full story at our sister site, Drug Delivery Business News. The post Intarcia slashes headcount after FDA rejects diabetes drug...
Source: Mass Device - February 5, 2018 Category: Medical Devices Authors: Sarah Faulkner Tags: Clinical Trials Diabetes Drug-Device Combinations Food & Drug Administration (FDA) Implants Pharmaceuticals Intarcia Therapeutics Source Type: news

Semaglutide Bests Exenatide in Type 2 Diabetes Semaglutide Bests Exenatide in Type 2 Diabetes
Subcutaneous injection of semaglutide provides superior results to exenatide extended release (ER), also administered subcutaneously, in patients who have diabetes inadequately controlled by oral agents, according to findings from an open-label trial.Reuters Health Information (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - January 12, 2018 Category: Consumer Health News Tags: Diabetes & Endocrinology News Source Type: news

BYDUREON(R) BCise(TM) Injectable Medicine Now Available In The US For Patients With Type-2 Diabetes
WILMINGTON, Del., Jan. 10, 2018 -- (Healthcare Sales & Marketing Network) -- AstraZeneca today announced that BYDUREON® BCise™ (exenatide extended-release) injectable suspension 2mg is now available in pharmacies across the United States. BYDUREON BCi... Biopharmaceuticals, Endocrinology, Product Launch AstraZeneca, BYDUREON BCise, exenatide (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - January 10, 2018 Category: Pharmaceuticals Source Type: news